Q-omics provides the consensus-scored MAPT-IT1 profile across patient tissues and cancer cell-line models. MAPT-IT1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MAPT-IT1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, MAPT-IT1 RNA expression shows 17,511 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, KIRC, and GBM as cancer lineages where MAPT-IT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPT-IT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPT-IT1 survival associations across molecular data types. MAPT-IT1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPT-IT1 RNA expression–survival associations across cancer types. High MAPT-IT1 expression shows unfavorable associations in UVM, UCEC and COAD, but favorable associations in BRCA, KIRC and PCPG. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MAPT-IT1 RNA expression.
This table summarizes MAPT-IT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MAPT-IT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPT-IT1 shows lower tumor expression in COAD, HNSC and STAD and higher tumor expression in KIRC, BRCA and LIHC. The KIRC box plot shows higher MAPT-IT1 RNA expression in tumor versus normal tissue (log2 FC = +0.132, t-test p < 0.001).
This table shows molecular features associated with MAPT-IT1 in patient tissues and cancer cell lines. In patient samples, MAPT-IT1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
